Abstract
In a mastocytoma model expressing mutant c-KIT, a combination of the c-KIT inhibitor dasatinib and an OX40-specific monoclonal antibody synergized in triggering a strong antitumor T-cell response that promoted curative therapeutic effects. Along with a number of other recent studies, these data support the notion that combining targeted agents with immunotherapy may constitute a promising approach for cancer therapy.
Original language | English (US) |
---|---|
Article number | e22730 |
Journal | OncoImmunology |
Volume | 2 |
Issue number | 2 |
DOIs |
|
State | Published - Feb 2013 |
Keywords
- Anti-OX40
- C-KIT mutant tumors
- Dasatinib
- Immunotherapy
- Targeted therapy
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology